Of note, the targeting of the mTOR pathway by rapamycin has already been discussed as a therapeutic approach in relapsing‐remitting multiple sclerosis (RRMS), which is the most common form of this demyelinating autoimmune disease and which aims modulate T cell immune responses in order to prevent relapses.11, 12. This evidence concerns the gene MTOR and autoimmune disease.